News & Press Releases
Filter by:
Competition Policy International featured Mintz’s addition of the five-partner antitrust litigation team led by Philip Iovieno and including Nicholas Gravante, Jr., Sean O’Shea, Michael Petrella, and Matthew Karlan.
Mintz Advises Satellos Bioscience in Its US$57.2 Million Initial US Public Offering
February 10, 2026
Mintz advised Satellos Bioscience Inc. in its US$57.2 million public offering in the United States and Canada and the concurrent listing of its common shares on the Nasdaq Global Market under the trading symbol “MSLE”. Satellos’ common shares are also listed on the Toronto Stock Exchange under the trading symbol “MSCL”.
PBMs Enter New Era of Legal Scrutiny
February 10, 2026
Law360 Healthcare Authority featured insights from Member Theresa Carnegie in an article focused on the Consolidated Appropriations Act of 2026 which introduces new regulations for pharmacy benefit managers, particularly aimed at fee and cost transparency.
The FDA Ad Crackdown Has Pharma's Attention. But Companies Aren't 'Radically Changing Course'—Yet
February 9, 2026
Joanne Hawana was quoted by Endpoints News in an article about how the pharma industry continues to spend hundreds of millions of dollars on ads despite a significant FDA crackdown on misleading consumer ads.
Reuters featured Mintz’s addition of the five-partner antitrust litigation team led by Philip Iovieno and including Nicholas Gravante, Jr., Sean O’Shea, Michael Petrella, and Matthew Karlan.
Mintz has further enhanced its high-powered litigation practice with a five-partner team led by Philip Iovieno and including Nicholas Gravante, Jr., Sean O’Shea, Michael Petrella, and Matthew Karlan.
